The Flow Cytometry Core Facility (FCCP) provides state-of-the-art flow cytometry services to researchers at the Cancer Center. Extensive user support is provided, consisting of daily instrument startup, maintenance and quality control;easy and reliable online scheduling systems;extensive training options;a site license for FlowJo analysis software;one-on-one consultations between individual researchers and Core Facility staff. These services include Operator-Assisted analysis on FACSCalibur and CyAn, Operator-Assisted cell sorting on two Aria and two MoFlo cell sorters, as well as User-Operated analysis on FACSCalibur, LSR II and Fortessa and User-Operated cell sorting on two Aria cell sorters. The combination of equipment and user support offers researchers opportunity to integrate flow cytometric analysis and cell sorting into their research projects. FCCP provides easy access to purified cell populations and to analysis of cellular subsets and processes, essential elements of many modern cell biology research projects. The presence of FCCP therefore plays an important role in the Center's capability to increase our knowledge of the processes that give rise to cancer, and to improve cancer diagnosis and therapy. The services and collaborative work provided by the FCCF has supported the research of 111 investigators in the past year. During the past grant period the work of the Core has contributed to 450 publications of researchers from 8 research programs. For example, the Flow Core was essential in helping the Rudensky lab demonstrate that regulatory T(Treg) cells integrate environmental cues that suppress particular types of Inflammation. These studies showed that Treg cell-mediated suppression of Th17-driven pathology is facilitated by activation of STAT3 downstream of interleukin 10-R (IL-1 OR) engagement of interleukin 10 (IL-10). This study demonstrated that IL-10 endows Treg cells with the ability to suppress pathogenic Thi7 cell responses. For these studies the Core provided expert flow analysis of STAT3 staining and cell sorting of Fox3-YFPT+ and Fox3-TFP- cells.
The FCCF provides essential services and instrumentation that enable Center investigators to simultaneously analyze multiple characteristics on large numbers of cells and to Isolate highly purified populations of cells that have specific features.
|Orlow, I; Satagopan, J M; Berwick, M et al. (2015) Genetic factors associated with naevus count and dermoscopic patterns: preliminary results from the Study of Nevi in Children (SONIC). Br J Dermatol 172:1081-9|
|Carey, Bryce W; Finley, Lydia W S; Cross, Justin R et al. (2015) Intracellular ?-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 518:413-6|
|Mosher, C E; Given, B A; Ostroff, J S (2015) Barriers to mental health service use among distressed family caregivers of lung cancer patients. Eur J Cancer Care (Engl) 24:50-9|
|Navi, Babak B; Reiner, Anne S; Kamel, Hooman et al. (2015) Association between incident cancer and subsequent stroke. Ann Neurol 77:291-300|
|Xu, Zhe; Wu, Chaochao; Xie, Fang et al. (2015) Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes. J Proteome Res 14:422-33|
|Xu, Hong; Cheng, Ming; Guo, Hongfen et al. (2015) Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody. Cancer Immunol Res 3:266-77|
|Gondo, Tatsuo; Poon, Bing Ying; Matsumoto, Kazuhiro et al. (2015) Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer. BJU Int 115:81-6|
|Ripley, R Taylor; McMillan, Robert R; Sima, Camelia S et al. (2014) Second primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinoma. Ann Thorac Surg 98:968-74|
|Ye, Jiangbin; Fan, Jing; Venneti, Sriram et al. (2014) Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov 4:1406-17|
|Lu, Zhigang; Xu, Jin; Xu, Mingming et al. (2014) Morphine regulates expression of *-opioid receptor MOR-1A, an intron-retention carboxyl terminal splice variant of the *-opioid receptor (OPRM1) gene via miR-103/miR-107. Mol Pharmacol 85:368-80|
Showing the most recent 10 out of 836 publications